FTO inhibition resulted in decreased expression of Mmps, which has shown promise as a therapeutic strategy for neuroprotection (Chen et al. 2009; Chaturvedi and Kaczmarek 2014), and potential changes in IGF1 signaling (Kok and Barton 2021), highlighting the significant decrease in Pten, the inhibition of which has been studied to protect against cognitive impairment (Tan et al. 2017), and a reduction of downstream signaling pathway of AKT and NF-κB target genes, which has been shown to be protective against HFD-induced metabolic dysregulation (Tseng 2024; Entezari et al. 2022). The gene discussed is AKT1; the disease is Cognitive impairment.